Beneficial Effects of Amnion-Chorion Stem Cell Grafting in the Long Term Management of Nonuremic Calciphylaxis Wounds

Successful Peripheral Blood Stem Cell (PBSC) Mobilisation with G-CSF in Patients with Chronic Myeloid Leukaemia Achieving Complete Cytogenetic Remission with Imatinib.

Blood ◽

10.1182/blood.v104.11.4652.4652 ◽

2004 ◽

Vol 104 (11) ◽

pp. 4652-4652

Author(s):

A.M. Carella ◽

Maria T. Corsetti ◽

Carlo Bodenizza ◽

Francesco Iuliano ◽

Giulia Pucci ◽

...

Keyword(s):

Stem Cell ◽

Peripheral Blood Stem Cell ◽

The Other ◽

Cell Yield ◽

Molecular Tests ◽

Cytogenetic Remission ◽

Low Levels ◽

Term Management ◽

Hematological Remission

Abstract The clinical studies have demonstrated the efficacy of Imatinib in the induction of hematological remission, cytogenetic remission (CCR) and molecular reduction of the bcl-abl transcript as shown by RT-qPCR. Unfortunately, the optimal long-term management of patients who achieve CCR after Imatinib is unknown. It is unclear that Imatinib alone will prove to be curative and initial responders may eventually lose Imatinib responsiveness. Therefore it may be prudent to collect autologous PBSC in CCR patients treated with Imatinib with low levels of detectable leukemia analyzed by molecular tests. We evaluated G-CSF mobilisation of PBSC in 18 patients who have achieved CCR with Imatinib. Our data demonstrated that the target CD34+ cell yields of ≥ 2.0x106/kg was attained with G-CSF at the dose of 10 mg/kg/day in 4/8 (50%) patients during uninterrupted Imatinib therapy and in 8/10 (80%) when Imatinib was temporarily interrupted. Three patients (37%) in the first group and 7 patients (70%) in the second group achieved >1x106/kg CD34+ cell yield per apheresis. Twelve patients were evaluated on PBSC for bcr-abl by RT-qPCR. Three patients were negative and in the other 9 patients, a median of 0.20 (range, 0.02–8.6) remained detectable. These data compared favourably with a median of 0.04 (range, 0.02 – 0.86) of all measurements taken before mobilisation. There was no impact of G-CSF mobilisation on the CML as measured by cytogenetic and serial blood bcr-abl levels. In conclusion, PBSC mobilisation with Imatinib and G-CSF in CCR patients is feasible, CD34+ cell yield is significantly better with temporary withheld of Imatinib, G-CSF did not preferentially mobilize leukemic progenitors and leukemic burden did not show significant change in the months following G-CSF mobilisation.

Download Full-text

Cellular therapy promotes endogenous stem cell repair

Canadian Journal of Physiology and Pharmacology ◽

10.1139/y2012-115 ◽

2012 ◽

Vol 90 (10) ◽

pp. 1335-1344 ◽

Cited By ~ 4

Author(s):

Forum Kamdar ◽

Mohammad Nurulqadr Jameel ◽

Paul Score ◽

Jianyi Zhang

Keyword(s):

Stem Cells ◽

Stem Cell ◽

Cellular Therapy ◽

Ventricular Remodeling ◽

Left Ventricular Remodeling ◽

Left Ventricular ◽

Lv Function ◽

Beneficial Effects ◽

Cellular Transplantation

Cellular transplantation for cardiac repair has emerged as an exciting treatment option for patients with myocardial infarction (MI) and heart failure. Animal models of post-infarction left ventricular remodeling have demonstrated an improvement in left ventricular (LV) function, decrease in scar size, and amelioration of adverse cardiac remodeling after stem cell transplantation. These beneficial effects occur despite minimal engraftment and negligible differentiation of transplanted cells. Evidence of the heart capability to self-renew continues to mount; however, the extent to which this occurs is still unclear. Although there is a specific population of cardiac stem cells capable of differentiating into cardiomyocytes, they alone are not capable of fully regenerating tissue damaged by MI. Therefore, paracrine mechanisms may be responsible for activating endogenous stem cells to promote regeneration and prevent apoptosis. These structural beneficial effects may reduce regional wall stresses, consequently leading to long-term host myocardium gene/protein expression changes, which may subsequently result in improvement in LV function.

Download Full-text

Long-term management of leukocyte adhesion deficiency type III without hematopoietic stem cell transplantation

Haematologica ◽

10.3324/haematol.2017.186304 ◽

2018 ◽

Vol 103 (6) ◽

pp. e264-e267 ◽

Cited By ~ 5

Author(s):

Paul Saultier ◽

Sarah Szepetowski ◽

Matthias Canault ◽

Céline Falaise ◽

Marjorie Poggi ◽

...

Keyword(s):

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Leukocyte Adhesion ◽

Leukocyte Adhesion Deficiency ◽

Hematopoietic Stem ◽

Deficiency Type ◽

Term Management

Download Full-text

Mesenchymal Stem Cells: The Magic Cure for Intraventricular Hemorrhage?

Cell Transplantation ◽

10.3727/096368916x694193 ◽

2017 ◽

Vol 26 (3) ◽

pp. 439-448 ◽

Cited By ~ 13

Author(s):

Won Soon Park ◽

So Yoon Ahn ◽

Se In Sung ◽

Jee-Yin Ahn ◽

Yun Sil Chang

Keyword(s):

Stem Cell ◽

Intraventricular Hemorrhage ◽

Neonatal Intensive Care ◽

Brain Injuries ◽

Therapeutic Potential ◽

Protective Action ◽

Preclinical Study ◽

Beneficial Effects ◽

Study Results

Severe intraventricular hemorrhage (IVH) remains a major cause of mortality and long-term neurologic morbidities in premature infants, despite recent advances in neonatal intensive care medicine. Several preclinical studies have demonstrated the beneficial effects of mesenchymal stem cell (MSC) transplantation in attenuating brain injuries resulting from severe IVH. Because there currently exists no effective intervention for severe IVH, the therapeutic potential of MSC transplantation in this intractable and devastating disease is creating excitement in this field. This review summarizes recent progress in stem cell research for treating neonatal brain injury due to severe IVH, with a particular focus on preclinical data concerning important issues, such as mechanism of protective action and determining optimal source, route, timing, and dose of MSC transplantation, and on the translation of these preclinical study results to a clinical trial.

Download Full-text

Drug Profile: Synadrin

Journal of International Medical Research ◽

10.1177/030006057300100312 ◽

1973 ◽

Vol 1 (3) ◽

pp. 204-209 ◽

Cited By ~ 8

Author(s):

J Eric Murphy

Keyword(s):

Endoplasmic Reticulum ◽

Calcium Transport ◽

Clinical Investigation ◽

Sympathetic Stimulation ◽

Dosage Range ◽

Cardiac Effects ◽

Beneficial Effects ◽

Uptake Of Noradrenaline ◽

Term Management

Synadrin (prenylamine lactate) is well established in the long-term management and prophylaxis of angina pectoris. It moderates the cardiac effects of sympathetic stimulation by decreasing the uptake of noradrenaline at the sympathetic nerve endings in the myocardium, and by slowing calcium transport through the endoplasmic reticulum. Extensive clinical investigation and usage has shown Synadrin to have beneficial effects in angina within a narrow dosage range and without frequent or troublesome side-effects.

Download Full-text